Zacks Research Has Positive Estimate for Novavax Q2 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Equities research analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for shares of Novavax in a research note issued to investors on Tuesday, January 28th. Zacks Research analyst S. Ganoria now anticipates that the biopharmaceutical company will post earnings of $0.44 per share for the quarter, up from their previous forecast of $0.39. The consensus estimate for Novavax’s current full-year earnings is ($1.31) per share. Zacks Research also issued estimates for Novavax’s Q2 2026 earnings at $0.07 EPS and FY2026 earnings at $0.39 EPS.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million for the quarter, compared to analyst estimates of $65.80 million. Novavax’s revenue for the quarter was down 54.8% on a year-over-year basis. During the same period last year, the business posted ($1.26) earnings per share.

Other research analysts have also issued research reports about the stock. Jefferies Financial Group lowered their price objective on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, October 16th. B. Riley reiterated a “buy” rating and set a $26.00 price target (up from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.83.

Novavax Price Performance

Novavax stock opened at $8.81 on Thursday. Novavax has a 52 week low of $3.53 and a 52 week high of $23.86. The company’s 50-day moving average price is $8.81 and its two-hundred day moving average price is $10.84.

Insider Buying and Selling at Novavax

In other news, Director Rachel K. King sold 4,150 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the sale, the director now owns 14,770 shares in the company, valued at $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James F. Young sold 5,400 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares of the company’s stock, valued at approximately $414,080. This trade represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,150 shares of company stock valued at $119,641. Corporate insiders own 1.00% of the company’s stock.

Hedge Funds Weigh In On Novavax

Several institutional investors and hedge funds have recently bought and sold shares of NVAX. Spire Wealth Management acquired a new stake in shares of Novavax during the fourth quarter worth approximately $29,000. Amalgamated Bank boosted its stake in shares of Novavax by 26.9% during the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,036 shares during the period. KBC Group NV grew its holdings in shares of Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 3,917 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Novavax by 38.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,598 shares in the last quarter. Finally, US Bancorp DE increased its stake in shares of Novavax by 3,538.8% in the third quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 11,961 shares during the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.